(Site Map)
(Search Poppink.com)
Star Power
|
Eating Disorder Recovery at Poppink.com is dedicated to offering support, inspiration, education and treatment opportunities for people with eating disorders and those who love them. Please see our terms of use. Eating Disorder Recovery at Poppink.comInformation about various dugs and medications that may relate to people with eating disordersThese links are offered to readers for informational purposes only. Always seek the advice of your physician or other qualified healthcare providers regarding any questions you may have about a medical condition or use of any medication."Clenbuterol: It's for my horse. His asthma's bad" The newest L.A. desperation diet is rumoured to be a veterinary medication by Nancy MacDonald | Apr 09, 2007 Maclean's Magazine, Canada September 15, 2003 Antidepressants Need Stronger Pediatric Use Warnings, Advisory Panel Concludes By Lisa Richwine Reuters Health Information; Medscape from Web MD "BETHESDA, Md. (Reuters) Sept 15 - Antidepressants such as Paxil and Prozac should come with strong warnings that they raise the risk of suicidal thoughts and behavior in some children and teen-agers, a U.S. advisory panel concluded on Tuesday. The U.S. Food and Drug Administration's panel of outside experts voted 15-8 to recommend warnings on the drug labels set off in a "black box," the strongest type of warning the government uses for prescription drugs." for full article please go to: http://www.medscape.com/viewarticle/489269?src=mp September 2, 2004 New study finds leptin plays a key role in women’s health "Research shows hormone can restore reproductive function, suggests role in treating infertility, eating disorders, bone loss A new study has found that leptin plays a critical role in women’s reproductive and neuroendocrine health and suggests a future for the hormone in treating a number of conditions including exercise-induced bone loss, eating disorders and some cases of infertility. Led by researchers at Beth Israel Deaconess Medical Center (BIDMC) and Massachusetts General Hospital (MGH), the findings are described in the September 2 issue of The New England Journal of Medicine. See full article in Innovations Report from Beth Israel Deaconess Medical Center" - August 2004 The FDA and several drug manufacturers altered and made additions to several drug warning labels in recent months. Some of these drugs may relate to medications used in treating eating disorders. See below links for more detailed information. The antidepressant Venlafaxine (Effexor) label now states that adult and pediatric patients with major depressive disorders may be at risk of increased depression and/or the emergence of suicidal ideation and behavior. The abrupt discontinuation of Effexor could cause new symptoms. The Risperdal (risperidone) label now describes the increased risk of hyperglycemia and diabetes to patients taking these medicines. Patients treated with these atypical antipsychotics who have a diagnosis of diabetes mellitus or with risk factors for diabetes (eg, obesity, family history of diabetes) should be monitored regularly for worsening of glucose control. (This may be of particular interest to patients who suffer from both an eating disorder and diabetes.) A case-control study, published in the Archives of Internal Medicine, finds an association between the use of antipsychotics and increased risk of sudden cardiac death. The revised label for Zelnorm, a medication used for women with irritable bowel syndrome (IBS), now states: "Serious consequences of diarrhea, including hypovolemia, hypotension and syncope have been reported in the clinical studies and during marketed use of Zelnorm. In some cases, these complications have required hospitalization for rehydration. Zelnorm should be discontinued immediately in patients who develop hypotension or syncope. Zelnorm should not be initiated in patients who are currently experiencing or frequently experience diarrhea." Depo-Provera decreases bone mineral density. article from: Planned Parenthood.org Metabolic Disorders in Schizophrenia: Relationship to Atypical Antipsychotic Treatment In Medscape Psychiatry & Mental Health Schizophrenia Expert Column Posted 07/28/2004 by Henry A. Nasrallah, MD; Martin L. Korn, MD Antipsychotics Linked to Sudden Cardiac Death CME In Mescape Today Release Date: June 29, 2004; Valid for credit through June 29, 2005 News Author: Laurie Barclay, MD CME Author: Désirée Lie, MD, MSEd Effexor (Venlafaxine) Updates In Remedy Find Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. by Theisen FM, Linden A, Konig IR, Martin M, Remschmidt H, Hebebrand J. Clinical Research Group, Department of Child and Adolescent Psychiatry, University of Marburg, Marburg, Federal Republic of Germany. frank.theisen@med.uni-marburg.de Researchers concluded "that clozapine/olanzapine may induce binge eating and full blown eating disorders which may have predictive value for weight gain. For future research in this field we suggest a novel DSM-IV research classification "Medication-induced eating disorders". In Journal of Neural Transmission 2003 Jan;110(1):111-21. FDA Safety Labeling Changes: Decadron, Duramorph, Infumorph, and Others In Medscape from WEB MD Yael Waknine Aug. 11, 2004 FDA Updates Zelnorm Labeling with New Risk Information U.S. Food and Drug Administration: Department of Health and Human Services April 28, 2004 2004 Safety Alert: Risperdal (risperidone) U.S. Food and Drug Administration: Department of Health and Human Services Public Health Advisory: Antidepressant Use in Children, Adolescents, and Adults Audience: Neuropsychiatric healthcare professionals and consumers The FDA asked manufacturers of the following antidepressant drugs to include in their labeling a Warning statement that recommends close observation of adult and pediatric patients for worsening depression or the emergence of suicidality when treated with these agents. The drugs that are the focus of this new Warning are: Prozac (fluoxetine); Zoloft (sertraline); Paxil (paroxetine); Luvox (fluvoxamine); Celexa (citalopram); Lexapro (escitalopram); Wellbutrin (bupropion); Effexor (venlafaxine); Serzone (nefazodone); and Remeron (mirtazapine). Public Health Advisory - FDA March 22, 2004 Subject:Worsening depression and suicidality in patients being treated with antidepressant medications FDA Public Health Advisory - March 22, 2004 Antidepressant Use in Children, Adolescents, and Adults FDA Drug Information Page - March 22, 2004 (On many FDA pages you can use the FDA search to look up a particular drug or topic of interest specific to you.) FDA Home Page: www.fda.gov FDA Recalls, Market Withdrawals and Safety Alerts FDA MedWatch E-list FDA MedWatch The FDA Safety Information and Adverse event Reporting Program Return to poppink.com home page Joanna Poppink,
MFT, licensed marriage and family therapist,
Poppink.com strives to make your navigation and use
of this site as simple and straightforward as possible. If
you experience any difficulties or notice any errors when using this site
please let us know. Click here: Problem Report
|
